Skip to main content
Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on RheumNow.com. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?
To TDM or Not in Rheumatology?

Therapeutic Drug Monitoring (TDM), especially for biologic therapies, has become a stand

Dr. John Cush RheumNow

4 years 3 months ago
To TDM or Not in Rheumatology? Therapeutic Drug Monitoring (TDM), especially for biologic therapies, has become a standard in gastroenterology, but shunned by most rheumatologists. But now, EULAR has a recommendation... https://t.co/u86Vd8bFGr #MedEdTwitter https://t.co/IpKqPoWM9R
Watch: Adherence to Rheumatoid Therapies

Dr. Michaud presents Adherence to Rheumatoid Therapies at the RheumNow Live 20

Dr. John Cush RheumNow

4 years 3 months ago
Watch: Adherence to Rheumatoid Therapies Dr. Michaud presents Adherence to Rheumatoid Therapies at the RheumNow Live 2022 meeting held in March. #MedEd https://t.co/sCCnx82ptN https://t.co/GJE0Ktwm7B
Visit @RheumNow podcast channel & hear experts from the #SLEEducatorsNetwork review a new framework for defining dis

Dr. John Cush RheumNow

4 years 3 months ago
Visit @RheumNow podcast channel & hear experts from the #SLEEducatorsNetwork review a new framework for defining disease modification in SLE and why there’s a need to consider therapies that modify the immunologic mechanisms of SLE. Sponsored by GSK USMA https://t.co/6HiO63Rthd https://t.co/7rjgj1WqGj
The cardiovascular (CV) risks of inflammation and gout are well known, but until recently hasn't been tied to calcium pyrophosphate deposition (CPPD) disease. A recent EHR study shows that acute CPPD crystal arthritis was significantly associated with elevated risks for non-fatal CV events.
Watch: Juvenile Spondyloarthritis

Dr. Pamela Weiss demystifies juvenial SpA and discusses the unique aspects of the d

Dr. John Cush RheumNow

4 years 3 months ago
Watch: Juvenile Spondyloarthritis Dr. Pamela Weiss demystifies juvenial SpA and discusses the unique aspects of the disease. https://t.co/xa2mO0fdzq #MedEd https://t.co/6JVUGRx5Go
1049 non-diabetic hospitalized gout pts (2014 -2020); saw an inverse relationship betw CKD & NAFLD, & increasei

Dr. John Cush RheumNow

4 years 3 months ago
1049 non-diabetic hospitalized gout pts (2014 -2020); saw an inverse relationship betw CKD & NAFLD, & increaseing negative associations w/ NAFLD severity (mild OR 0.392; Mod: 0.379; Severe 0.148). NAFLD negatively assoc w/ CKD risk in gout https://t.co/5fuIiO1LwM https://t.co/Jp8CjWkn5m
NEJM : 40 yoM 2 wk hx scaly foot rash, joint swelling & LBP. 1 wk ago had diarrhea & urethral discharge. Feet s

Dr. John Cush RheumNow

4 years 3 months ago
NEJM : 40 yoM 2 wk hx scaly foot rash, joint swelling & LBP. 1 wk ago had diarrhea & urethral discharge. Feet show keratoderma blenorrhagicum; PSO on scalp, trunk, hands, nail changes, +swollen joints, CRP 59/L, UA sterile pyuria, B27+ https://t.co/GgKWIbL9Br https://t.co/m0fbg8mJUc
A large US population based study shows that psoriasis is associated with a higher risk of nonalcoholic fatty liver disease (NAFLD). The study included 5672 US patients, aged 20 to 59 years from the National Health and Nutrition Examination Survey. The main outcome was NAFLD, defined as a US fatty liver index score greater than 30.
RT @Lupusreference: 🆒 Current indications for #biologics, in inflammatory rheumatic diseases 🔎 such as rheumatoid

Laurent ARNAUD Lupusreference

4 years 3 months ago
🆒 Current indications for #biologics, in inflammatory rheumatic diseases 🔎 such as rheumatoid #arthritis, axSPA, PsA etc... A useful checklist ✅ to keep in the pocket prepared with @DocFelten #Rheumatology #EULAR2022 https://t.co/cfc4VaF6GZ
A Roadmap for Investigating Preclinical Autoimmunity Using Patient-Oriented and Epidemiologic Study Designs: Example of

Dr. John Cush RheumNow

4 years 3 months ago
A Roadmap for Investigating Preclinical Autoimmunity Using Patient-Oriented and Epidemiologic Study Designs: Example of Rheumatoid Arthritis - a comprehensive overview of studies of preclinical RA and risk of RA https://t.co/DKbDXkvFyQ
RT @MeralElRamahiMD: @ERheumat @mukes_dr @drMsayan @vikasagrIMMUNO @DurgaPrasannaM1 @LatikaGupta_ @Janetbirdope @AshimaM

Meral K. El Ramahi, MD MeralElRamahiMD

4 years 3 months ago
@ERheumat @mukes_dr @drMsayan @vikasagrIMMUNO @DurgaPrasannaM1 @LatikaGupta_ @Janetbirdope @AshimaMakol @sclerodermaUM @PanktiMehta24 @ACR_Journals Sclerotylosis… Huriez Syndrome? Triad of 1) sclerodactyly 2) palmoplantar keratoderma 3) nail changes. High susceptibility of early onset squamous cell cancer of affected areas
×